Trial reportTrials2026
Rivaroxaban versus low-molecular-weight heparin and fondaparinux for preventing deep vein thrombosis after total knee arthroplasty in high-altitude residents: a randomized controlled trial.
Trial report in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHigh-altitude residence (defined as ≥ 1500 m above sea level) is associated with chronic hypoxia and increased thrombotic risk. This study aimed to evaluate the comparative efficacy and safety of rivaroxaban, low-molecular-weight heparin (LMWH), and fondaparinux for preventing deep vein thrombosis (DVT) after total knee arthroplasty (TKA) in long-term high-altitude residents.
methodsIn this randomized controlled trial, 90 high-altitude residents undergoing primary TKA were randomly assigned to one of three groups: rivaroxaban (group A), LMWH (group B), or fondaparinux (group C). The primary outcome was the incidence of postoperative DVT assessed by duplex ultrasonography on postoperative day 14. Secondary outcomes included coagulation indicators (PT, APTT, FIB, PLT, D-dimer), inflammatory markers (CRP, PCT, IL-6, ESR, WBC), knee circumference, intraoperative blood loss, and bleeding-related adverse events.
resultsDVT incidence was 0% in the rivaroxaban group, compared with 16.7% in the LMWH group and 13.3% in the fondaparinux group (P = 0.016). On postoperative day 14, D-dimer levels were significantly lower in the rivaroxaban group than in LMWH (P < 0.001) and fondaparinux (P < 0.001) and lower in fondaparinux than LMWH (P < 0.001). PT and APTT were higher in the rivaroxaban group compared with LMWH (PT P < 0.001, APTT P = 0.012) and fondaparinux (PT P < 0.001, APTT P = 0.035). FIB and PLT showed no significant differences. CRP and PCT were significantly lower with rivaroxaban than LMWH (CRP P < 0.001, PCT P < 0.001) and fondaparinux (CRP P = 0.018, PCT P = 0.018), while IL-6, ESR, and WBC showed no group differences. Intraoperative blood loss and bleeding complications were comparable across groups.
conclusionAmong high-altitude residents undergoing TKA, rivaroxaban demonstrated superior efficacy in preventing postoperative DVT and reducing inflammatory response without increasing bleeding risk. These findings contribute important evidence to guide anticoagulant selection in populations living at high altitude, who face unique thrombotic challenges due to chronic hypoxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.